AIM: We evaluated preoperative serum carcinoembryonic antigen (CEA) as a prognostic factor for colorectal cancer and determined when surveillance of this marker was useful. METHODS: Serum CEA was measured preoperatively in 1,263 patients who underwent curative resection for colorectal cancer at 3-month intervals for the first 2 postoperative years and at 6-month intervals thereafter. Mean follow-up was 48 months (range 1-156 months). RESULTS: The 5-year disease-free survival was less in patients with a high preoperative serum CEA level (P<0.0001). Among patients with a tumor recurrence, 38.5% had high follow-up serum CEA levels. The number of patients with high postoperative serum CEA levels exceeded the number of patients with high preoperative levels. High preoperative and follow-up serum CEA levels were independent prognostic factors for tumor recurrence (P=0.003 and P<0.001, respectively). In patients with high preoperative serum CEA levels, CEA surveillance had a 92.3% positive predictive value (PPV) and a 96.1% negative predictive value (NPV). The mean interval between postoperative serum CEA elevation and the diagnosis of a tumor recurrence [diagnostic interval (DI)] was 2.5 months (range 5-17 months). The DI was 0 in 18.8% of patients with a tumor recurrence. CONCLUSION: High serum CEA levels preoperatively and at follow-up are prognostic factors for colorectal cancer. Postoperative serum CEA surveillance is used most effectively when patients have high preoperative serum CEA levels. Considering the DI of 0 in 18.8% of the patients, the current CEA surveillance schedule might be changed.
AIM: We evaluated preoperative serum carcinoembryonic antigen (CEA) as a prognostic factor for colorectal cancer and determined when surveillance of this marker was useful. METHODS: Serum CEA was measured preoperatively in 1,263 patients who underwent curative resection for colorectal cancer at 3-month intervals for the first 2 postoperative years and at 6-month intervals thereafter. Mean follow-up was 48 months (range 1-156 months). RESULTS: The 5-year disease-free survival was less in patients with a high preoperative serum CEA level (P<0.0001). Among patients with a tumor recurrence, 38.5% had high follow-up serum CEA levels. The number of patients with high postoperative serum CEA levels exceeded the number of patients with high preoperative levels. High preoperative and follow-up serum CEA levels were independent prognostic factors for tumor recurrence (P=0.003 and P<0.001, respectively). In patients with high preoperative serum CEA levels, CEA surveillance had a 92.3% positive predictive value (PPV) and a 96.1% negative predictive value (NPV). The mean interval between postoperative serum CEA elevation and the diagnosis of a tumor recurrence [diagnostic interval (DI)] was 2.5 months (range 5-17 months). The DI was 0 in 18.8% of patients with a tumor recurrence. CONCLUSION: High serum CEA levels preoperatively and at follow-up are prognostic factors for colorectal cancer. Postoperative serum CEA surveillance is used most effectively when patients have high preoperative serum CEA levels. Considering the DI of 0 in 18.8% of the patients, the current CEA surveillance schedule might be changed.
Authors: Soo Young Lee; Jeong Seon Jo; Hun Jin Kim; Chang Hyun Kim; Jae-Kyun Ju; Young Jin Kim; Hyeong Rok Kim Journal: Int J Colorectal Dis Date: 2014-11-01 Impact factor: 2.571
Authors: Ondrej Fiala; Jindrich Finek; Tomas Buchler; Vit Martin Matejka; Lubos Holubec; Jana Kulhankova; Zbynek Bortlicek; Vaclav Liska; Ondrej Topolcan Journal: Target Oncol Date: 2015-12 Impact factor: 4.493
Authors: Ching-Wei D Tzeng; Aparna Balachandran; Mediha Ahmad; Jeffrey E Lee; Sunil Krishnan; Huamin Wang; Christopher H Crane; Robert A Wolff; Gauri R Varadhachary; Peter W T Pisters; Thomas A Aloia; Jean-Nicolas Vauthey; Jason B Fleming; Matthew H G Katz Journal: HPB (Oxford) Date: 2013-08-29 Impact factor: 3.647
Authors: Joan Manel Gasent Blesa; Javier Garde Noguera; Juan Bautista Laforga Canales; Vicent Giner Bosch; Antonio Alberola; Miguel Soler Tortosa; Miguel Peris Godoy; Jose Luis Sanchez; Mariano Provencio Pulla; Vicente Alberola Candel Journal: J Gastrointest Cancer Date: 2012-12
Authors: Ignazio Tarantino; Rene Warschkow; Bruno M Schmied; Ulrich Güller; Markus Mieth; Thomas Cerny; Markus W Büchler; Alexis Ulrich Journal: J Gastrointest Surg Date: 2016-04-11 Impact factor: 3.452